Current state of immunotherapy for non-small cell lung cancer.
about
Anaplastic lymphoma kinase rearrangements in non-small-cell lung cancer: novel applications in diagnostics and treatment.Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three casesHDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo.Erratum to current state of immunotherapy for non-small cell lung cancer.Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles.PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted?Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes.Antigen-specific primed cytotoxic T cells eliminate tumour cells in vivo and prevent tumour development, regardless of the presence of anti-apoptotic mutations conferring drug resistance.Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).Correlation of MET gene amplification and TP53 mutation with PD-L1 expression in non-small cell lung cancer.Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lung cancer.Immunotherapy in Advanced Non-small Cell Lung Cancer Patients: Ushering Chemotherapy Through the Checkpoint Inhibitors?New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trialsBroader indications for checkpoint inhibitors in NSCLC
P2860
Q39459182-406CEC4B-F203-401B-8E19-AB5B51D61DAFQ41072491-71FBFD45-1B23-45DF-A415-DF1093EBC953Q45073629-DFBE9243-55A2-4198-8CA7-3D7C82659591Q45721063-BE0AE668-3694-4B6F-8583-5B5928F5F484Q47093855-FBB7B5CD-96E3-4FA2-A60B-F08E94AEA004Q48620065-A262ADEC-7B13-493D-893F-39167D164C4CQ50345931-34B45BB2-13A8-47FF-B306-EA089BCA047DQ53685196-D375E6A9-FC76-4511-AF28-57808B7FAD48Q55008531-FA35C3A9-E613-4D9B-B64F-FA3F9834A43BQ55177170-25F63F05-77F9-4EF3-9F59-093464BD0038Q55507456-2FA16F0C-7616-41C6-8C5F-02EAFF1F8EADQ58699431-21692C10-68FE-44DC-95F4-A1AD7014678AQ58740200-95257AE6-95F3-4F8F-9A4F-07DB6924F952Q58768522-72C3C7A9-9F68-4AA6-8A7F-5FE02DBE9135Q58771161-7415C964-5C15-4329-8067-55553B688D1C
P2860
Current state of immunotherapy for non-small cell lung cancer.
description
2017 nî lūn-bûn
@nan
2017 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Current state of immunotherapy for non-small cell lung cancer.
@ast
Current state of immunotherapy for non-small cell lung cancer.
@en
type
label
Current state of immunotherapy for non-small cell lung cancer.
@ast
Current state of immunotherapy for non-small cell lung cancer.
@en
prefLabel
Current state of immunotherapy for non-small cell lung cancer.
@ast
Current state of immunotherapy for non-small cell lung cancer.
@en
P2093
P2860
P356
P1476
Current state of immunotherapy for non-small cell lung cancer.
@en
P2093
Joseph Aisner
Jyoti Malhotra
Salma K Jabbour
P2860
P304
P356
10.21037/TLCR.2017.03.01
P577
2017-04-01T00:00:00Z